PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Cook, Stéphane
TI  - Satisfactory Angiographic and Clinical Outcomes with the Everolimus-Eluting BVS
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 20--21
VI  - 14
IP  - 30
4099  - http://mdc.sagepub.com/content/14/30/20.short
4100  - http://mdc.sagepub.com/content/14/30/20.full
AB  - New generation drug-eluting stents (DESs) are increasingly efficient and safe, while the ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS) is thought to reduce long-term complications, including neoatherosclerosis and very late stent thrombosis. The objective of the Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stent trial [EVERBIO II; NCT01711931] was to compare the efficacy of the BVS with the best-in-class new generation DESs.